CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly earnings results on February 12, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $-1.37, missing the consensus estimate of $-1.20 by $0.17 per share. Revenue came in at $864.0K, missing the estimate of $3.9M.
CRISPR Therapeutics's stock moved following the earnings release. The stock currently trades at $51.97 with a market capitalization of $5.1B.